vs
CENTRUS ENERGY CORP（LEU）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是CENTRUS ENERGY CORP的1.4倍（$197.9M vs $146.2M），REPLIGEN CORP同比增速更快（13.6% vs -3.6%），REPLIGEN CORP自由现金流更多（$17.6M vs $-58.0M），过去两年CENTRUS ENERGY CORP的营收复合增速更高（82.9% vs 14.4%）
Centrus Energy Corp是美国能源企业，主营核电站所需核燃料供应，同时专注于离心技术的研发与落地推广，生产可应用于商业、政府场景及国家安全领域的浓缩铀产品。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
LEU vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.4倍
$146.2M
营收增速更快
RGEN
高出17.2%
-3.6%
自由现金流更多
RGEN
多$75.6M
$-58.0M
两年增速更快
LEU
近两年复合增速
14.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $146.2M | $197.9M |
| 净利润 | — | $13.3M |
| 毛利率 | 23.9% | 52.5% |
| 营业利润率 | 8.8% | 9.0% |
| 净利率 | — | 6.7% |
| 营收同比 | -3.6% | 13.6% |
| 净利润同比 | — | 143.9% |
| 每股收益（稀释后） | $0.52 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LEURGEN
| Q4 25 | $146.2M | $197.9M | ||
| Q3 25 | $74.9M | $188.8M | ||
| Q2 25 | $154.5M | $182.4M | ||
| Q1 25 | $73.1M | $169.2M | ||
| Q4 24 | $151.6M | $174.1M | ||
| Q3 24 | $57.7M | $154.9M | ||
| Q2 24 | $189.0M | $154.1M | ||
| Q1 24 | $43.7M | $151.3M |
净利润LEURGEN
| Q4 25 | — | $13.3M | ||
| Q3 25 | $3.9M | $14.9M | ||
| Q2 25 | $28.9M | $14.9M | ||
| Q1 25 | $27.2M | $5.8M | ||
| Q4 24 | — | $-30.3M | ||
| Q3 24 | $-5.0M | $-654.0K | ||
| Q2 24 | $30.6M | $3.3M | ||
| Q1 24 | $-6.1M | $2.1M |
毛利率LEURGEN
| Q4 25 | 23.9% | 52.5% | ||
| Q3 25 | -5.7% | 53.2% | ||
| Q2 25 | 34.9% | 50.0% | ||
| Q1 25 | 45.0% | 53.6% | ||
| Q4 24 | 40.8% | 26.1% | ||
| Q3 24 | 15.4% | 50.0% | ||
| Q2 24 | 19.3% | 49.8% | ||
| Q1 24 | 9.8% | 49.5% |
营业利润率LEURGEN
| Q4 25 | 8.8% | 9.0% | ||
| Q3 25 | -22.2% | 8.9% | ||
| Q2 25 | 21.7% | 7.6% | ||
| Q1 25 | 28.0% | 3.9% | ||
| Q4 24 | 29.7% | -17.7% | ||
| Q3 24 | -13.2% | -5.1% | ||
| Q2 24 | 11.2% | 1.0% | ||
| Q1 24 | -24.3% | 1.3% |
净利率LEURGEN
| Q4 25 | — | 6.7% | ||
| Q3 25 | 5.2% | 7.9% | ||
| Q2 25 | 18.7% | 8.2% | ||
| Q1 25 | 37.2% | 3.4% | ||
| Q4 24 | — | -17.4% | ||
| Q3 24 | -8.7% | -0.4% | ||
| Q2 24 | 16.2% | 2.2% | ||
| Q1 24 | -14.0% | 1.4% |
每股收益（稀释后）LEURGEN
| Q4 25 | $0.52 | $0.24 | ||
| Q3 25 | $0.19 | $0.26 | ||
| Q2 25 | $1.59 | $0.26 | ||
| Q1 25 | $1.60 | $0.10 | ||
| Q4 24 | $3.26 | $-0.55 | ||
| Q3 24 | $-0.30 | $-0.01 | ||
| Q2 24 | $1.89 | $0.06 | ||
| Q1 24 | $-0.38 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0B | $767.6M |
| 总债务越低越好 | $1.2B | $542.2M |
| 股东权益账面价值 | $765.1M | $2.1B |
| 总资产 | $2.4B | $2.9B |
| 负债/权益比越低杠杆越低 | 1.54× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资LEURGEN
| Q4 25 | $2.0B | $767.6M | ||
| Q3 25 | $1.6B | $748.7M | ||
| Q2 25 | $833.0M | $708.9M | ||
| Q1 25 | $653.0M | $697.2M | ||
| Q4 24 | $671.4M | $757.4M | ||
| Q3 24 | $194.3M | $784.0M | ||
| Q2 24 | $227.0M | $809.1M | ||
| Q1 24 | $209.3M | $780.6M |
总债务LEURGEN
| Q4 25 | $1.2B | $542.2M | ||
| Q3 25 | $1.2B | $537.9M | ||
| Q2 25 | $390.0M | — | ||
| Q1 25 | $389.5M | — | ||
| Q4 24 | $472.5M | $525.6M | ||
| Q3 24 | $83.5M | — | ||
| Q2 24 | $86.5M | — | ||
| Q1 24 | $86.5M | — |
股东权益LEURGEN
| Q4 25 | $765.1M | $2.1B | ||
| Q3 25 | $363.1M | $2.1B | ||
| Q2 25 | $359.1M | $2.1B | ||
| Q1 25 | $213.9M | $2.0B | ||
| Q4 24 | $161.4M | $2.0B | ||
| Q3 24 | $76.4M | $2.0B | ||
| Q2 24 | $76.6M | $2.0B | ||
| Q1 24 | $33.8M | $2.0B |
总资产LEURGEN
| Q4 25 | $2.4B | $2.9B | ||
| Q3 25 | $2.2B | $2.9B | ||
| Q2 25 | $1.3B | $2.9B | ||
| Q1 25 | $1.3B | $2.9B | ||
| Q4 24 | $1.1B | $2.8B | ||
| Q3 24 | $591.0M | $2.8B | ||
| Q2 24 | $668.2M | $2.9B | ||
| Q1 24 | $750.0M | $2.8B |
负债/权益比LEURGEN
| Q4 25 | 1.54× | 0.26× | ||
| Q3 25 | 3.23× | 0.26× | ||
| Q2 25 | 1.09× | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | 2.93× | 0.27× | ||
| Q3 24 | 1.09× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 2.56× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-48.4M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $-58.0M | $17.6M |
| 自由现金流率自由现金流/营收 | -39.7% | 8.9% |
| 资本支出强度资本支出/营收 | 6.6% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $31.3M | $93.9M |
8季度趋势，按日历期对齐
经营现金流LEURGEN
| Q4 25 | $-48.4M | $25.7M | ||
| Q3 25 | $10.1M | $48.1M | ||
| Q2 25 | $52.8M | $28.6M | ||
| Q1 25 | $36.5M | $15.0M | ||
| Q4 24 | $57.9M | $39.2M | ||
| Q3 24 | $-33.2M | $49.3M | ||
| Q2 24 | $7.0M | $42.2M | ||
| Q1 24 | $5.3M | $44.7M |
自由现金流LEURGEN
| Q4 25 | $-58.0M | $17.6M | ||
| Q3 25 | $5.7M | $43.4M | ||
| Q2 25 | $49.2M | $21.5M | ||
| Q1 25 | $34.4M | $11.4M | ||
| Q4 24 | $57.2M | $33.6M | ||
| Q3 24 | $-34.2M | $42.3M | ||
| Q2 24 | $6.1M | $37.4M | ||
| Q1 24 | $3.8M | $36.4M |
自由现金流率LEURGEN
| Q4 25 | -39.7% | 8.9% | ||
| Q3 25 | 7.6% | 23.0% | ||
| Q2 25 | 31.8% | 11.8% | ||
| Q1 25 | 47.1% | 6.8% | ||
| Q4 24 | 37.7% | 19.3% | ||
| Q3 24 | -59.3% | 27.3% | ||
| Q2 24 | 3.2% | 24.3% | ||
| Q1 24 | 8.7% | 24.0% |
资本支出强度LEURGEN
| Q4 25 | 6.6% | 4.1% | ||
| Q3 25 | 5.9% | 2.5% | ||
| Q2 25 | 2.3% | 3.9% | ||
| Q1 25 | 2.9% | 2.1% | ||
| Q4 24 | 0.5% | 3.2% | ||
| Q3 24 | 1.7% | 4.5% | ||
| Q2 24 | 0.5% | 3.1% | ||
| Q1 24 | 3.4% | 5.5% |
现金转化率LEURGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | 2.59× | 3.23× | ||
| Q2 25 | 1.83× | 1.92× | ||
| Q1 25 | 1.34× | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.23× | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LEU
| Separative Work Units | $111.0M | 76% |
| Services | $21.8M | 15% |
| Other | $13.4M | 9% |
RGEN
暂无分部数据
